Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three Strikes For Generic Advair With An FDA CRL For Sandoz

Executive Summary

Novartis' generic drug unit confirmed the receipt of a complete response letter from the US FDA for a generic version of GlaxoSmithKline's Advair, following similar CRLs for Mylan and Hikma.

Advertisement

Related Content

Eight Things To Know From Novartis' Third Quarter Call
Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
Novartis Sale Of US Oral Generics Unit Seems Unlikely
Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch
Mylan Preparing Response To Generic Advair CRL, And It Needs A Win
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel